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Introduction: There is limited information on effective disease monitoring for prompt interventions in
childhood nephrotic syndrome. We examined the feasibility and effectiveness of a novel text messaging
system (SMS) for disease monitoring in a multicenter, prospective study.
Methods: A total of 127 patients <19 years with incident nephrotic syndrome were enrolled in the ongoing
Nephrotic Syndrome Study Network between June 2015 and March 2018. Text messages soliciting home
urine protein results, symptoms, and medication adherence were sent to a designated caregiver (n ¼ 116)
or adolescent patient (n ¼ 3). Participants responded by texting. Feasibility of SMS was assessed by SMS
adoption, retention, and engagement, and concordance between participant-reported results and laboratory/clinician assessments. The number of disease relapses and time-to-remission data captured by
SMS were compared with data collected by conventional visits.
Results: A total of 119 of 127 (94%) patients agreed to SMS monitoring. Retention rate was 94%, with a
median follow-up of 360 days (interquartile range [IQR] 353–362). Overall engagement was high, with a
median response rate of 87% (IQR, 68–97). Concordance between SMS-captured home urine protein results and edema status with same-day in-person study visit was excellent (kappa values 0.88 and 0.92,
respectively). SMS detected a total of 108 relapse events compared with 41 events captured by scheduled
visits. Median time to remission after enrollment was 22 days as captured by SMS versus 50 days as
captured by scheduled visits.
Conclusion: SMS was well accepted by caregivers and adolescent patients and reliably captured nephrotic
syndrome disease activity between clinic visits. Additional studies are needed to explore the impact of
SMS on disease outcomes.
Kidney Int Rep (2019) 4, 1066–1074; https://doi.org/10.1016/j.ekir.2019.04.026
KEYWORDS: caregivers; children; health status; mobile health; nephrotic syndrome; text messaging
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diopathic nephrotic syndrome is one of the most
common chronic glomerular diseases in children,
characterized by heavy proteinuria leading to
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hypoalbuminemia, edema, and hypercholesterolemia.1
The vast majority of children are treated empirically
with corticosteroids on initial presentation, and most
respond to treatment with resolution of proteinuria
and correction of biochemical disturbances. However,
80% to 90% of the children initially sensitive to corticosteroids will experience disease relapse, with half
relapsing frequently or becoming dependent on corticosteroids to maintain remission.2–5 During relapses or
Kidney International Reports (2019) 4, 1066–1074
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active disease, patients can suffer from edema, acute
kidney injury, serious infections, and thromboembolic
events.1
Management of children with nephrotic syndrome
thus entails long-term outpatient surveillance and
adherence to treatment. Home care is a key component
of disease management and includes the important task
of checking urine for protein with test strips. Timely
detection of proteinuria is important, as it signiﬁes
disease relapse and allows physicians to initiate or
adjust corticosteroid therapy before the development of
edema and disease-related complications. Tracking the
urine for resolution of proteinuria also is important so
that treatments can be adjusted promptly once remission is achieved. Currently, physicians rely on patients
and caregivers to report home urine testing results
between clinic visits; yet poor adherence with urine
testing, inaccurate documentation, and delayed
communication with providers are frequent barriers for
effective monitoring and timely medication adjustment.6 There are currently no proven efﬁcacious interventions to improve disease monitoring in childhood
nephrotic syndrome.
Mobile health (mHealth) is a rapidly growing ﬁeld in
disease monitoring and management. Currently, 95%
of all US adults own cellphones, and 77% own smartphones.7 In addition, 95% of adolescents report either
owning a smartphone or having access to one.8 The
ubiquitous presence of mobile phones with advanced
computing and communication capabilities make them
excellent tools in helping patients manage chronic
medical conditions.9 Most cellphones provide SMS, also
known as text messaging, which is an inexpensive
method of asynchronous communication that is less
intrusive than phone calls.10 We examined the feasibility and effectiveness of using SMS for disease
monitoring in childhood nephrotic syndrome in a
study conducted through the Nephrotic Syndrome
Study Network (NEPTUNE), part of the National Institutes of Health Rare Disease Clinical Research
Network. We hypothesized that SMS would enable
better characterization of nephrotic syndrome disease
activity as compared with conventional in-person visits
due to rapid and nonintrusive symptom tracking inbetween visits.
MATERIALS AND METHODS
Data Sources and Study Population
The NEPTUNE study (NCT01209000) is a multicenter,
longitudinal cohort study conducted in the United
States and Canada that prospectively collects demographic and clinical information, as well as biospecimens, on patients with nephrotic syndrome. The
Kidney International Reports (2019) 4, 1066–1074
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NEPTUNE study protocol does not dictate disease
treatment. Full details of the study design have been
published elsewhere.11 The SMS patient surveillance
procedure was implemented among all NEPTUNE pediatric participants younger than 19 years with incident nephrotic syndrome who did not receive a biopsy
for diagnosis. Eligibility criteria included individuals
with clinical diagnosis of nephrotic syndrome, less
than 30 days of immunosuppressive therapy for
nephrotic syndrome, and documentation of nephrotic
range proteinuria (urinalysis >2þ protein or random
urine protein: creatinine ratio >2 g/g) and edema or
serum albumin <3 g/dl. Exclusion criteria included
prior solid organ or bone marrow transplant, end-stage
kidney disease, secondary nephrotic syndrome (e.g.,
nephrotic syndrome resulting from systemic lupus erythematosus), clinical or histologic evidence of other
renal disease (e.g., Alport syndrome, Nail Patella syndrome, diabetic nephropathy), or genitourinary malformations with vesicoureteral reﬂux or renal
dysplasia, unwillingness or inability to give informed
consent, or institutionalization. Urine protein dipsticks
(ProAdvantage Urine Reagents Strips, Model P080012,
Nashville, TN) were provided to all participants for
home urine protein monitoring. For the small number
of NEPTUNE participants without a working mobile
phone or for those with a preference to use a studyspeciﬁc phone, the study provided a phone to enable
participation (participants who received a study
phone ¼ 2). Participants opting to use their own phone
were provided a monthly stipend of $15 to offset the
cost of the study-related text messages. Participants
were enrolled from June 2015 through March 2018,
with follow-up for the current analysis through
May 2018. The study was approved by the institutional
review boards at all participating sites and conducted
in accordance with the Declaration of Helsinki. Consent
from legal guardians and minor assent (where appropriate) were obtained from all study participants.
SMS Monitoring and Study Protocol
Text messages were sent to either the parent/guardian
(n ¼ 116) or participant $12 years old (n ¼ 3)
depending on participant preference to more closely
reﬂect how a mobile health tool would be adopted by
families living with nephrotic syndrome. The messages
were automatically delivered to the participants via a
central system for 1 year after enrollment into
NEPTUNE. Messages were delivered in the language
preferred by the participants (English, 116 participants; Spanish, 3 participants) and at the time of day
and days of the week preferred by the participants.
Questions on urine test results and symptoms of
swelling were sent daily for the ﬁrst 90 days, followed
1067
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Symptoms (sent daily for the first 90 days, then weekly):
•

What is your child’s urine protein today?


•

Does your child have swelling today?


•

0=negative/trace; 1=1+; 2=2+; 3=3+ or
higher; 9=No reading

0=No; 1=Yes

If yes: Where is the swelling? (mark all that apply)
(daily ×90d, then weekly)


1=face; 2=abdomen; 3=leg; 4=privates;
5=feet/ankles; 6=all over

Missed school/work (sent weekly):
•

In the last 7 days, how many days has your child missed school?


•

0=0 days; 1=1 day; 2; 3; 4; 5; 6; 7=7 days; 9=Don't Know

In the last 7 days, how many days have you missed work or school because of your child's illness?


0=0 days; 1=1 day; 2; 3; 4; 5; 6; 7=7 days; 9=Don't Know

Recent health issues (sent weekly):
•

In the last 7 days, has your child experienced an infection, allergies or significant stress?


0=No; 1=Infection; 2=Allergy; 3=Stress (Mark all that apply)

Adherence (sent weekly):


Are you taking your immunosuppression medication as prescribed by your doctor?


0=No; 1=Yes

Figure 1. Study text messages and sample screen shot.

by weekly for the rest of the year. Questions on missed
work/school, issues with infections/allergies/stressors,
and adherence with medications were sent weekly.
Participants responded to the texts by texting back a
numeric answer. Figure 1 displays the messages sent to
participants with a sample screen shot. The SMS system could be paused for planned vacations or during
hospitalizations by the study coordinator. The
participant-reported urine protein results were stored
centrally in the NEPTUNE electronic data management
system (NEPTUNE-LINK) and analyzed. The back-end
managing system generated e-mail alerts to the study
staff for recurrence of proteinuria $2þ for 3 days in a
row indicating new disease relapse, if participants reported new edema, or if the participant reported not
taking medications. The alert message included a
recommendation for the study team to follow up with
participants, but treatment and additional actions were
left to the discretion of the study site investigators. The
SMS system also generated alerts to the study staff if no
responses were received from the participants for >1
week. Study site investigators were instructed to contact participants to make sure there were no logistic or
technical barriers for SMS response (e.g., lost Internet
access, planned vacation, unplanned hospitalization).
Other than responding to the text messages and
1068

receiving study-provided urine dipsticks, participants
were instructed to follow their treating physician’s
instructions for disease monitoring and communication. In particular, the NEPTUNE study did not speciﬁcally instruct participants on when to contact their
treating physician.
In-person study visits in the ﬁrst year included
screening, baseline, and quarterly visits that captured
the following information: demographic characteristics;
medical, family, and social history; disease relapses and
hospitalizations; physical examination; past and current medications; patient-reported outcomes; and results of clinical laboratory testing. Disease relapse
events were recorded by direct participant inquiry and
review of provider documentation, with start and end
dates, if available.
Outcomes and Variables
The primary aims of this study were to determine the
feasibility of SMS for childhood nephrotic syndrome
monitoring and its ability to increase detection of
relapse/remission as compared with in-person visits.
We examined the acceptability of the SMS system
among caregivers/participants as deﬁned by the adoption, engagement, and retention of SMS, as well as the
concordance of SMS information with laboratory results
Kidney International Reports (2019) 4, 1066–1074
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and physician assessment. We compared the detection
of disease relapses/remissions by SMS versus conventional scheduled in-person visits. Variables included the
following: proportion of caregivers/patients who
refused to participant in the SMS procedure (adoption),
proportion of caregivers who dropped out of the SMS
study (retention), response rate to texts as deﬁned by
the percentage of texts answered on a daily or weekly
basis (engagement), change in response rate over time
(engagement over time), concordance of participantreported urine protein results via the SMS system
with same-day in-clinic urinalysis results, concordance
of participant-reported edema status with same-day
clinic physical examination ﬁndings, number of disease relapses captured by SMS or by history collected
during in-person study visits, and time to disease
remission after study enrollment captured by SMS or by
history collected during in-person study visits.
Time to remission after study enrollment as collected
by SMS was deﬁned as 3 consecutive reports of negative/trace urine protein during the ﬁrst 90 days of daily
SMS prompts or 1 report of negative/trace urine protein following prior positive ﬁndings during weekly
SMS prompts. Disease relapse as collected by SMS was
deﬁned as 3 consecutive reports of $2þ urine protein
or a single report of 3þ urine protein with edema
following a period of negative/trace urine protein results during the ﬁrst 90 days of daily SMS prompts; or
1 report of $2þ urine protein following a period of
negative/trace urine protein during weekly SMS
prompts. Disease relapse events were captured with
start and end dates (indicating time to remission) during scheduled in-person visits by participant recall and
review of physician documentation (if available). Estimated glomerular ﬁltration rate was calculated from
serum creatinine at enrollment using the bedside
Schwartz equation.12
The secondary aim was to determine predictors of
SMS acceptance by examining changes in responsiveness over time as related to patient demographic and
baseline clinical characteristics: age, sex, race, ethnicity,
primary language, urine protein-to-creatinine ratio,
estimated glomerular ﬁltration rate, and serum albumin.
Statistical Analysis
Patients’ clinical and demographic characteristics were
described as frequencies and percentages and medians
and IQRs. Overall SMS response rate was calculated as
the proportion of days in which an SMS query was sent
to which the patient responded. To examine response
rate over time, we examined weekly response graphically for the overall cohort and stratiﬁed by clinical
and demographic characteristics. A participant was
Kidney International Reports (2019) 4, 1066–1074
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considered to have “responded” for a given week if he
or she answered at least 1 text during that week.
Changes in response rates over time were assessed
by generalized linear mixed models. The association
between text responses and patients’ clinical and demographic characteristics was analyzed using univariate generalized linear mixed models for the ﬁrst 90 days
(daily SMS) and from day 91 to 365 (weekly SMS). P
values <0.05 were considered to be statistically signiﬁcant. Patients who had not yet had 1 year of followup were censored on the day of the last text message
delivered, date of study withdrawal, or the date of
withdrawal from the SMS data collection. Administrative censoring occurred on the date of the data
extraction: May 23, 2018.
Agreement between participant-reported urine protein results and the same-day urinalysis was determined by concordance, kappa, and weighted kappa.
These were ﬁrst calculated for exact agreement in
values. A sensitivity analysis considered differences of
1 level between patient- and clinician-reported values
as concordant (e.g., 1þ from the SMS report, 2þ from
the clinic urinalysis).
Number of disease relapses per patient were calculated for relapses captured by the SMS system and
clinical report forms from in-person visits, and
compared using a Poisson regression. Time to disease
remission after initial enrollment was estimated by
Kaplan-Meier plots for both SMS-captured data versus
clinical report form data from in-person visits, and
compared using log-rank tests.
Statistical analyses were performed using SAS
version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Patient Characteristics
Between June 2015 and March 2018, 127 pediatric patients were enrolled in the NEPTUNE incident children’s cohort at the time of disease onset but before
kidney biopsy. On average, patients were enrolled into
the NEPTUNE incident children’s cohort 23 days after
onset of disease (IQR, 11–35). Figure 2 shows participant
ﬂow: 8 (6%) patients declined participation in the SMS
study, and 7 subsequently withdrew after enrolling.
Baseline characteristics of the participants at the time
of enrollment are summarized in Table 1. The median
age was 4 years with 60% of patients 0 to 4 years old.
The cohort was 43% female, 23% black/African
American, and 17% Hispanic. At the time of enrollment, the median urine protein-to-creatinine ratio was
9.9 g/g (IQR, 6.5–20.2), the median estimated glomerular ﬁltration rate was 110 ml/min per 1.73 m2 (IQR,
94–152), and the median serum albumin was 1.5 g/dl
1069
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127 Enrolled in cNEPTUNE

8 Declined participation in the SMS study

119 Enrolled in SMS
7 Withdrew
• 3 Withdrew from NEPTUNE study
• 4 Withdrew from SMS data collection

112 SMS respondents retained

Figure 2. Participant ﬂow in Nephrotic Syndrome Study Network (NEPTUNE) short message service (SMS) study. cNEPTUNE, children’s
nonbiopsy incident cohort.

Table 1. Characteristics of NEPTUNE pediatric nonbiopsy incident
cohort (cNEPTUNE) within the SMS study
Participant characteristics
Age (yr), median (IQR)

SMS study participants
(n [ 119)
4 (2–6)

Age (yr), n (%)
0–4

72 (61)

5–9

31 (26)

10–18
Female, n (%)

16 (13)
51 (43)

Race, n (%)
Multiracial

8 (7)

Asian/Asian American

9 (8)

Black/African American

27 (23)

Native Hawaiian/other Paciﬁc Islander

1 (1)

White/Caucasian

59 (50)

Unknown

15 (13)

Hispanic, n (%)

20 (17)

Primary English speaker, n (%)

107 (90)

UP:C (g/g), median (IQR)

9.9 (6.5–20.2)

UP:C (g/g), n (%)
1–2

4 (3)

2–3

2 (2)

$3.0

97 (82)

Unknown
eGFRa (ml/min per 1.73 m2), median (IQR)

16 (13)
110 (94–152)

eGFRa (ml/min per 1.73 m2), n (%)
>90

94 (79)

60–90

21 (18)

30–60

4 (3)

<30
Serum albumin (g/dl), median (IQR)

0 (0)
1.5 (1.2–2.0)

Serum albumin (g/dl), n (%)
$3.0

2 (2)

<3.0

110 (92)

Unknown

7 (6)

eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; NEPTUNE, the
Nephrotic Syndrome Study Network; SMS, short messaging service; UP:C, urine
protein-to-creatinine ratio.
a
Estimated GFR is calculated from serum creatinine at enrollment using the Beside
Schwartz formula.12
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(IQR, 1.2–2.0). All participants were treated with corticosteroids on presentation per local standard of care.
Comparisons of the characteristics of those who
declined SMS study participation (n ¼ 8) or withdrew
from NEPTUNE (n ¼ 3) or SMS participation (n ¼ 4)
after initial consent to the participants who remained in
the SMS study (n ¼ 112) are included in Supplementary
Appendix S1. There were no statistically signiﬁcant
differences in baseline characteristics between participants who remained in the SMS study and those who
declined or withdrew from the study.
SMS System Acceptance
Patient/caregiver adoption of the technology in cNEPTUNE was high, with 119 of 127 (94%) patients
agreeing to participate in the SMS portion of the study.
Median duration of SMS study follow-up was 360 days
(IQR, 353–362), and respondents provided a median of
100 responses (IQR, 78–121). Seven of 119 participants
(6%) subsequently withdrew from NEPTUNE/SMS
study. Thus, overall, the retention was 96% with a
median follow-up of 1 year.
Median patient-level responsiveness was high (i.e.,
87%; IQR, 68%–97%). Response frequency over time is
shown in Figure 3. There was no change in response rate
during the daily SMS period from day 1 to day 90 (odds
ratio [OR] per 30 days: 1.4; 95% conﬁdence interval [CI]:
0.9–1.9; P ¼ 0.07), and response rates were >90% in
each week. However, there was a signiﬁcant decrease in
the proportion responding after day 90 when participants transitioned from daily to weekly SMS messages.
Thus, 94% of participants responded to SMS assessment
in week 10 compared with 80% in week 20, 59% in
week 30, 61% in week 40, and 52% in week 50. There
was a statistically signiﬁcant decline in the likelihood of

Kidney International Reports (2019) 4, 1066–1074

CLINICAL RESEARCH

a100

b 100

c

Response rate (%)

Response rate (%)

Response rate (%)

C-s Wang et al.: SMS for Nephrotic Syndrome

80
60
40
20

80
60
40
20
0

0

10

80
60
40
20
0

0

0

100

20

30
40
50
Week
Day 90: Transition from daily to weekly SMS

10

20

30
40
50
Week
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Day 90: Transition from daily to weekly SMS

0
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Week
English (n=107)
Other (n=12)
Day 90: Transition from daily to weekly SMS
10

Figure 3. Weekly short message service (SMS) response rate over time (n ¼ 119) among the (a) entire cohort, (b) Hispanic versus nonHispanic participants, and (c) primary English speakers versus nonprimary English speakers. Participants were considered “responders” in a
given week if they responded to at least 1 SMS message.

response over time in the day 91 to 365 period (OR per
30 days: 0.7; 95% CI: 0.6–0.7; P < 0.001).
Concordance of Participant-Reported Data and
Same-Day In-Clinic Laboratory Testing and
Physician Examination
Urine protein levels reported by the participants via
SMS exactly agreed with urinalyses on the same day in
105 of 135 (77%) instances (Table 2), with a weighted
kappa of 0.76, indicating good agreement. Although
SMS-reported urine protein levels are deemed to be “in
agreement” with urinalyses if they are only 1 level off,
the concordance and kappa increased to 94% and 0.88,
respectively, indicating excellent agreement. In a
sensitivity analysis limited to 48 same-day SMS-urinalysis results performed after day 60 of the study,
there was 100% concordance (kappa ¼ 1.0), suggesting
the concordance improved over time.
Edema status (yes or no) reported via SMS was
conﬁrmed by same-day physical examination in 27 of
28 (96%) of visits, with kappa of 0.92, indicating
excellent agreement (Table 2).

Disease Relapse and Remission Detection by
SMS Compared With In-Person Clinic Visits
Figure 4 displays the percentage of patients with
nephrotic range protein (2þ or higher by dipstick) at a
given follow-up time-point as captured by SMS
reporting versus conventional in-person clinic followup. The SMS system captured more disease relapse
events compared with relapses identiﬁed by study
visits: total number of relapse events was 108 versus
41, total number of patients with relapse was 55 versus
41, and number of relapse events per patient with at
least 1 relapse was 2 (1, 4) versus 1 (1, 1; P < 0.01). In
addition, without SMS data capture, the median estimated time to disease remission following study
enrollment was 50 days (IQR, 21–150). However, the
more frequent proteinuria data captured by SMS
enabled the generation of an improved time-toremission estimate of 22 days (IQR, 13–64; Figure 5).
Predictors of Responsiveness Over Time
Results of unadjusted models examining the relationship
between patient clinical/demographic characteristics
and SMS response are shown in Table 3. During the

Table 2. Concordance of participant-reported home urine protein
test results and edema via SMS with same-day in-clinic
assessments
SMS-captured home urine
protein results

Same-day clinic urinalysis protein results
Negative/Trace

1D

2D

‡3D

67a

2b

1c

4c

1þ

4b

6a

4b

2c

2þ

2

c

0

b

5

a

10b

0

c

1

c

0

b

27a

Negative/trace

$3þ
SMS-captured edema self-assessment

Same-day physician edema
assessment
Edema

No edema

Edema

8

0

No edema

1

19

SMS, short message service.
a
Exact agreement between the SMS-captured home urine protein result and the sameday clinic urinalysis protein result.
b
SMS-captured home urine protein result and the same-day clinic urinalysis protein
result differed by 1 level.
c
Discrepancy of 2 or more levels.
Kidney International Reports (2019) 4, 1066–1074

Figure 4. Percentage of patients with nephrotic range proteinuria
as captured by short message service (SMS) reporting versus inperson clinic visits.
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(Figure 3b) and English versus non-English primary
speakers (Figure 3c). In our cohort, 8 of 20 (40%)
Hispanic individuals were non-English primary
speakers, compared with 4 of 99 (4%) of non-Hispanic
individuals. Because these 2 variables have a high degree of overlap, we examined the relationship between
Hispanic ethnicity and response rate after adjusting for
primary language. A multivariable generalized linear
mixed model with both ethnicity and language found
ethnicity (OR: 0.2; 95% CI: 0.1–0.3; P < 0.01), but not
non-English language (OR: 0.5; 95% CI: 0.1–3.4; P ¼
0.45) to be a signiﬁcant predictor of response rate.
Figure 5. Time to remission after study enrollment by short
message service (SMS)–captured urine protein results versus
participant reporting during in-person study visits. CR, complete
remission.

daily SMS period, responsiveness was high in all
participants and there were no statistically signiﬁcant
differences in response rate by age, sex, race,
ethnicity, primary language, proteinuria, estimated
glomerular ﬁltration rate, or albumin at enrollment (all
P $ 0.05). However, during the weekly SMS period
between day 91 and 365, Hispanic ethnicity and nonEnglish primary language were negative predictors of
responsiveness (Table 3). OR of response in Hispanic
versus non-Hispanic individuals was 0.1 (95% CI:
0.1–0.2; P < 0.001) and OR of response in non-English
primary speakers versus English primary speakers
was 0.1 (95% CI: 0.1–0.6; P < 0.01), even though
messages were sent in the recipient’s preferred
language.
Figure 3 shows the responsiveness over time among
those of Hispanic versus non-Hispanic ethnicity
Table 3. Univariate analysis of patient characteristics and SMS
response over time (n ¼ 119)
First 90 days

Days 91--365

OR (95% CI)

P

OR (95% CI)

P

Age (per 5 yr)

1.0 (0.4–2.2)

0.92

1.0 (0.5–2.3)

0.93

Female

0.8 (0.2–2.5)

0.67

1.5 (0.5–5.2)

0.49

0.4 (0.1–1.9)

0.25

Patient characteristics

Race
Black/African American
White/Caucasian
Other

0.15
0.3 (0.1–1.1)

0.06

0.44

REF

REF

REF

REF

0.4 (0.1–1.8)

0.23

1.1 (0.3–4.7)

0.89

Hispanic

0.4 (0.1–1.5)

0.15

0.1 (0.1–0.2)

<0.001

Non-English primarya

1.6 (0.2–12.2)

0.67

0.1 (0.1–0.6)

0.01

UP:C (per 1 g/g)

1.0 (1.0–1.0)

0.53

1.0 (1.0–1.0)

0.98

eGFRb (per 30 ml/min
per 1.73 m2)

1.0 (0.7–1.4)

0.92

0.9 (0.6–1.1)

0.28

Serum albumin (per 1 g/dl)

0.9 (0.3–2.3)

0.77

1.5 (0.4–3.0)

0.94

CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; OR, odds ratio; REF,
reference; SMS, short messaging service; UP:C, urine protein-to-creatinine ratio.
a
SMS respondent characteristic.
b
Estimated GFR is calculated from serum creatinine at enrollment using the Beside
Schwartz formula.12
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DISCUSSION
In this prospective, multicenter study, we demonstrated
that text messaging is a feasible tool for home disease
monitoring in childhood nephrotic syndrome. Patient/
caregiver adoption of the technology was high, with
most patients agreeing to participate, and excellent
retention on follow-up at 1 year. In addition, we found
that participating subjects were very engaged with the
SMS system over the entire period of observation.
Concordance between SMS-captured home urine protein testing results with same-day urinalyses was high
and improved over time, supporting the validity of
patient-reported information via SMS. We acknowledge
that there is no validated tool to enable standardized
assessment of edema; however, our ﬁndings suggest
there is good concordance between caregiver and
physician evaluation of this physical ﬁnding in children
with nephrotic syndrome. Furthermore, the SMS system captured more disease relapse events and more
precise information on time to remission as compared
with conventional in-person visits, offering a more accurate account of nephrotic syndrome disease activity.
Although overall engagement with the SMS system
was high in our cohort, we did ﬁnd that engagement
over time decreased after the initial 90 days. A notable
change from the ﬁrst 90 days of follow-up to the period
between 90 days and 12 months was text message
frequency. Texts were sent daily during the ﬁrst 90
days but weekly thereafter. As a result, it is unclear
whether the drop off in responsiveness was due to time
trends or the change in frequency of messaging during
later periods. A limitation of our study is that adequate
engagement was deﬁned as at least 1 response per
week. After the ﬁrst 90 days, texts were sent only once
a week, reducing the opportunities for the participant
to respond, which may have affected their engagement
as deﬁned. Further study is needed to determine the
optimal text message frequency to sustain user
engagement and align with informational requirements. We found that Hispanic individuals and
Kidney International Reports (2019) 4, 1066–1074
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non-English primary speakers showed signiﬁcantly
reduced response rate over time after 90 days, despite
the availability of a Spanish version of the SMS system.
A review by Chesser et al.13 found that eHealth literacy, pertaining to operational and navigational skills
and the ability to choose and critically evaluate available electronic information, is lower in underserved
populations, including Hispanic individuals and those
with limited English language. It is possible that factors
reducing eHealth literacy have negatively affected SMS
engagement in our patients; however, there were
several unexamined factors in our study that may also
affect engagement, including educational level,
perceived utility and value, motivation, and privacy
concerns.14 We attempted to remove technical and logistic issues by providing free phones as needed and
stipends for text message–related fees and periodically
reaching out to families who were not responding to
texts. These measures likely improved SMS adoption,
retention, and engagement, but it is unlikely that all
technical/logistic barriers were removed. More indepth evaluations are needed to fully explore the inﬂuences and strategies to promote mHealth engagement
and acceptance in childhood nephrotic syndrome.
Our analysis comparing the ability of SMS to capture
disease relapse/remission compared with standard inperson visits was likely biased by the uncontrolled
study design. The SMS system triggered alerts to the
study staff of new disease relapses and edema, and
the study staff in turn reached out to participants to
follow up on their disease status. These actions likely
increased caregiver and provider awareness of new
disease relapses and medical chart documentation, such
that more events will be captured by our deﬁnition of
conventional, in-person study visits (where relapse/
remission history is obtained from participant inquiry
and medical chart documentations). The differences in
the number of disease relapses and times to remission
captured by SMS versus in-person visits were likely
underestimated by this study. Our study was also
limited by the small patient numbers, including very
few adolescent self-respondents (n ¼ 3), which precluded our ability to perform adjusted analyses of
predictors of SMS engagement.
In summary, we found that SMS was well accepted
by caregivers and adolescent patients and reliably
captured nephrotic syndrome disease activity between
clinic visits. There is very limited published experience
on strategies and tools to improve childhood nephrotic
syndrome monitoring, although this disease is one of
the most common chronic kidney diseases with signiﬁcant negative impacts on ﬁnancial and psychosocial
status and quality of life.15–17 The relapsing-remitting
pattern among most children necessitates home urine
Kidney International Reports (2019) 4, 1066–1074

monitoring, the results of which are critical to support
timely treatment decisions and avert progression of
nephrotic syndrome symptoms and complications with
high morbidity due to delayed relapse therapy. With
the current encouraging ﬁndings of feasibility of SMS
use in childhood nephrotic syndrome, ongoing
research is needed to determine whether mHealth solutions can promote home monitoring and improve
nephrotic syndrome outcomes.
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